ArticleCell death discovery2017
iPS-derived MSCs from an expandable bank to deliver a prodrug-converting enzyme that limits growth and metastases of human breast cancers.
Article in Cell death discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- The New Approach to Treating Erectile Dysfunction: Stem Cell-Derived Extracellular Vesicles.International journal of nanomedicine · 2025Review
- iPSC-Derived MSCs Are a Distinct Entity of MSCs with Higher Therapeutic Potential than Their Donor-Matched Parental MSCs.International journal of molecular sciences · 2023Article
- Pluripotent-derived Mesenchymal Stem/stromal Cells: an Overview of the Derivation Protocol Efficacies and the Differences Among the Derived Cells.Stem cell reviews and reports · 2022Review
- Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine.World journal of stem cells · 2021Review
- SAR-CoV-2 infection, emerging new variants and the role of activation induced cytidine deaminase (AID) in lasting immunity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- Heat shock protein 20 promotes sirtuin 1-dependent cell proliferation in induced pluripotent stem cells.World journal of stem cells · 2021Article
- Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer.Stem cell research & therapy · 2021Article
- Cytidine deamination-induced perpetual immunity to SAR-CoV-2 infection is a potential new therapeutic target.International journal of medical sciences · 2021Review
- Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy.Frontiers in cell and developmental biology · 2021Review
- Need for Specialized Therapeutic Stem Cells Banks Equipped with Tumor Regression Enzymes and Anti-Tumor Genes.Journal of biomedical and allied research · 2020Article
- Clinical Relevance of RNA Editing to Early Detection of Cancer in Human.International journal of stem cell research and therapy · 2020Article
- Stem cell-derived extracellular vesicles: role in oncogenic processes, bioengineering potential, and technical challenges.Stem cell research & therapy · 2019Review
- Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism.Oncotarget · 2019Article
- The Dynamic Roles of Mesenchymal Stem Cells in Colon Cancer.Canadian journal of gastroenterology & hepatology · 2018Review
- Diagnostic and Therapeutic Potential of Extracellular Vesicles.Technology in cancer research & treatmentReview
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
One attractive strategy to treat cancers is to deliver an exogenous enzyme that will convert a non-toxic compound to a highly toxic derivative. The strategy was tested with viral vectors but was disappointing because the efficiency of transduction into tumor cells was too low. Recent reports demonstrated that the limitation can be addressed by using tissue-derived mesenchymal stromal cells (MSCs) to deliver enzyme/prodrug systems that kill adjacent cancer cells through bystander effects. Here we addressed the limitation that tissue-derived MSCs vary in their properties and are difficult to generate in the large numbers needed for clinical applications. We prepared a Feeder Stock of MSCs from induced pluripotent stem cells (iPSs) that provided an extensively expandable source of standardized cells. We then transduced the iPS-derived MSCs to express cytosine deaminase and injected them locally into a mouse xenogeneic model of human breast cancer. After administration of the prodrug (5-fluorocytosine), the transduced iPS-MSCs both limited growth of preformed tumors and decreased lung metastases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.